(Q37160706)

English

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

scientific article published on 17 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening (English)

1 reference

Europe PubMed Central

18 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

N Pashayan

1

0 references

Paul D P Pharoah

3

object named as

P Pharoah

1 reference

Europe PubMed Central

18 August 2017

8

object named as

D E Neal

1 reference

Europe PubMed Central

18 August 2017

author name string

S W Duffy

2

1 reference

Europe PubMed Central

18 August 2017

D Greenberg

4

1 reference

Europe PubMed Central

18 August 2017

J Donovan

5

1 reference

Europe PubMed Central

18 August 2017

R M Martin

6

1 reference

Europe PubMed Central

18 August 2017

F Hamdy

7

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

17 March 2009

1 reference

Europe PubMed Central

18 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

18 August 2017

100

1 reference

Europe PubMed Central

18 August 2017

7

1 reference

Europe PubMed Central

18 August 2017

1198-1204

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604973

0 references

Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Screening for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Does "clock" matter in prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Prostate-specific antigen testing accuracy in community practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Screening for prostate cancer: estimating the magnitude of overdetection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Significance of free prostate-specific antigen and gamma-seminoprotein in the screening of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

The value of prostatic specific antigen in prostate cancer screening in the community

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Breast cancer screening programmes: the development of a monitoring and evaluation system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

6 September 2017

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

14 September 2017

Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

14 September 2017

Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

14 September 2017

Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

29 September 2017

Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

27 June 2018

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

3 September 2018

Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

3 September 2018

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

3 September 2018

[Detection of cancer, sensitivity of the test and sensitivity of the screening program]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

3 September 2018

Asymptomatic incidence and duration of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670005

3 September 2018

Screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604973

21 January 2018

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

2 references

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604973

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/19293796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lead-time in prostate cancer screening (Finland)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19293796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/19293796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of prostate specific antigen for early stage prostate cancer detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19293796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitivity in cancer screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/19293796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604973

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37160706&oldid=2095527297"